SCHEMBL3869683

SCHEMBL3869683

Cc1cc(C(=O)Nc2ccccc2C(=O)Nc2n[nH]c3sc(C(=O)O)cc23)n[nH]1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR4 P22455 4/20 0.40
BDKRB1 P46663 1/20 0.39
KDM4E B2RXH2 1/20 0.39
PTPN2 P17706 1/20 0.38
PTPN1 P18031 1/20 0.38
PTPN6 P29350 1/20 0.38
CDC25B P30305 1/20 0.38
PTPN11 Q06124 1/20 0.38
RAB9A P51151 2/20 0.38
DAO P14920 1/20 0.38
HCAR2 Q8TDS4 1/20 0.38
KMT2A Q03164 2/20 0.38
ATM Q13315 2/20 0.38
KIT P10721 1/20 0.38
NPC1 O15118 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
MAPT P10636 1/20 0.37
MEN1 O00255 1/20 0.37
AURKA O14965 1/20 0.37
AURKB Q96GD4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3872653 0.88 ALDH1A1 (0.43) FGFR4KDM4ERAB9AKMT2AMAPT
SCHEMBL1778032 0.88 AURKA (0.42) FGFR4BDKRB1KDM4EKITAURKA
SCHEMBL3874232 0.86 PTPN2 (0.42) FGFR4KDM4EPTPN2PTPN1PTPN6
SCHEMBL3866586 0.86 POLB (0.42) FGFR4BDKRB1KDM4ERAB9AKMT2A
SCHEMBL3866786 0.86 KDM4E (0.48) KDM4ERAB9AKMT2AATMNPC1
SCHEMBL3871522 0.85 P2RY14 (0.47) KDM4EKMT2AATMMAPTMEN1
SCHEMBL3865998 0.84 ROCK1 (0.41) FGFR4KDM4ERAB9AKMT2ANPC1
SCHEMBL3870804 0.84 NPC1 (0.45) RAB9AKMT2ANPC1SMN1; SMN2MAPT
SCHEMBL1778788 0.84 FGFR4 (0.36) FGFR4KDM4ERAB9AKMT2ANPC1
SCHEMBL3866552 0.83 GRM4 (0.42) FGFR4BDKRB1KDM4ERAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904503-B1 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2013-11-06 EP claimed
US-20090149457-A1 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-06-11 US claimed
EP-1904503-A1 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.r.l. (IT) 2008-04-02 EP claimed
WO-2007009898-A1 1H-THIENO[2,3-C]PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2007-01-25 WO claimed
EP-1904503-B1 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2013-11-06 EP disclosed
US-20090149457-A1 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-06-11 US disclosed
EP-1904503-A1 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.r.l. (IT) 2008-04-02 EP disclosed
WO-2007009898-A1 1H-THIENO[2,3-C]PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2007-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149457-A1 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors CCNH, PDK1, MAP3K5 FGFR4 389/4885BDKRB1 421/4885KDM4E 2856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.